Viatris Inc. · NASDAQ:VTRS
Viatris — Mylan Laboratories — Lehman Brothers Seventh Annual Global Healthcare Conference 2004
13 slides from Viatris's conference presentation, Mar 3, 2004
Slide 1: Lehman Brothers Seventh Annual Global Healthcare Conference
Lehman Brothers Seventh Annual Global Healthcare Conference March 3, 2004
Slide 2: Forward Looking Statements
Forward Looking Statements These materials and accompanying statements of management address our intended future operations, our management's perspective on future trends in the pharmaceutical industry, and other matters concerning the prospects for our business. These materials and accompanying sta
Slide 3: Investing for the Future Creates Opportunities
Investing for the Future Creates Opportunities
Slide 4: Highlights of Last Year's Opportunities
Highlights of Last Year's Opportunities Commitment to build upon our leadership role in the generic industry Actively identify and develop technological exclusivities Identified opportunities which increased our portfolio of paragraph IV filings Capitalize on our capability to develop transdermal dr
Slide 5: Foundation of Our Growth
Foundation of Our Growth Outstanding Employees Exceptional Quality Premier Customer Service Manufacturing Excellence Depth of Legal Expertise Research & Development Expertise Research & Development Expertise Research & Development Expertise Research & Development Expertise Research & Development Exp
Slide 6: Investing in SG&A
Investing in SG&A Investing in SG&A 6 FY97 FY98 FY99 FY00 FY01 FY02 FY03 FY04 SG&A 79948 96708 124964 148688 151212 169913 173070 148153 in thousands 9 months Year-to-date
Slide 7: Investing in R&D
Investing in R&D FY97 FY98 FY99 FY00 FY01 FY02 FY03 FY04 R&d 43622 46278 61843 49121 64385 58847 86748 73933 7 7 in thousands 9 months Year-to-date
Slide 8: EPS and EPS Growth
FY97 FY98 FY99 FY00 FY01 FY02 FY03 FY04 EPS 0.23 0.36 0.4 0.52 0.13 0.91 0.97 0.94 0.23 EPS Growth EPS Growth 8 FY04 Guidance
Slide 9: Strong Pipeline of Opportunities
Strong Pipeline of Opportunities Over 200 products either filed or in development 40 applications pending FDA approval which represent approximately $29 billion in 2003 brand sales Potential first-to-file paragraph IV ANDAs currently representing approximately $9.3 billion in 2003 brand sales $9.3 b
Slide 10: Apomorphine Update
Apomorphine Update Anticipated trade name "Apokyn" Approvable letter received July 2, 2003 Response submitted to FDA Final approval pending FDA review PDUFA date: April 20, 2004 Anticipated launch fiscal 2005 Orphan drug designation Specialty distribution Plan to market via our existing 55 person Ne
Slide 11: Nebivolol
Nebivolol New generation ?-blocker with a unique profile for the US hypertension market Results of the completed Bertek NDA Development Program showed: Highly ? 1 selective (? 1 to ? 2 ratio over 300 to 1) Blood pressure lowering regardless of age, race or gender Side-effect profile similar to place
Slide 12: Fiscal 2005 Earnings Guidance
Fiscal 2005 Earnings Guidance Line Items Guidance Revenues Growth of 15 -20% Gross Margin Approx. 58 - 62% of Revenues R&D Approx. 6 - 8% of Revenues Selling & Marketing Approx. 6 - 8% of Revenues General & Administrative Approx. 9 - 11% of Revenues Operating Margin Approx. 37 - 40% of Revenues Tax
Slide 13: Mylan Laboratories Inc.
m MYLAN» LABORATORIES INC,
Mylan Laboratories — Lehman Brothers Seventh Annual Global Healthcare Conference 2004 on 6ix